( 0 1 0 1 O
exceptions 1 11 1 11 O
are 12 15 12 15 O
squamous 16 24 16 24 B-cancer
and 25 28 25 28 O
basal 29 34 29 34 B-cancer
cell 35 39 35 39 I-cancer
carcinomas 40 50 40 50 I-cancer
of 51 53 51 53 I-cancer
the 54 57 54 57 I-cancer
skin 58 62 58 62 I-cancer
and 63 66 63 66 O
carcinoma 67 76 67 76 B-cancer
in 77 79 77 79 I-cancer
situ 80 84 80 84 I-cancer
of 85 87 85 87 I-cancer
the 88 91 88 91 I-cancer
cervix 92 98 92 98 I-cancer
, 98 99 98 99 O
or 100 102 100 102 O
malignancy 103 113 103 113 B-cancer
that 114 118 114 118 O
in 119 121 119 121 O
the 122 125 122 125 O
opinion 126 133 126 133 O
of 134 136 134 136 O
the 137 140 137 140 O
investigator 141 153 141 153 O
, 153 154 153 154 O
with 155 159 155 159 O
concurrence 160 171 160 171 O
with 172 176 172 176 O
the 177 180 177 180 O
sponsor 181 188 181 188 O
's 188 190 188 190 O
medical 191 198 191 198 O
monitor 199 206 199 206 O
, 206 207 206 207 O
is 208 210 208 210 O
considered 211 221 211 221 O
cured 222 227 222 227 O
with 228 232 228 232 O
minimal 233 240 233 240 O
risk 241 245 241 245 O
of 246 248 246 248 O
recurrence 249 259 249 259 O
) 259 260 259 260 O

Each 0 4 261 265 O
prior 5 10 266 271 B-treatment
line 11 15 272 276 I-treatment
of 16 18 277 279 I-treatment
therapy 19 26 280 287 I-treatment
may 27 30 288 291 O
consist 31 38 292 299 O
of 39 41 300 302 O
one 42 45 303 306 O
or 46 48 307 309 O
more 49 53 310 314 O
agents 54 60 315 321 O
and 61 64 322 325 O
may 65 68 326 329 O
include 69 76 330 337 O
induction 77 86 338 347 B-treatment
, 86 87 347 348 O
hematopoietic 88 101 349 362 B-treatment
stem 102 106 363 367 I-treatment
cell 107 111 368 372 I-treatment
transplantation 112 127 373 388 I-treatment
, 127 128 388 389 O
and/or 129 135 390 396 O
maintenance 136 147 397 408 B-treatment
therapy 148 155 409 416 I-treatment
. 155 156 416 417 O
Radiotherapy 157 169 418 430 B-treatment
, 169 170 430 431 O
bisphosphonates 171 186 432 447 B-treatment

IgA 0 3 448 451 B-cancer
, 3 4 451 452 O
IgD 5 8 453 456 B-cancer
, 8 9 456 457 O
or 10 12 458 460 O
IgE 13 16 461 464 B-cancer
multiple 17 25 465 473 I-cancer
myeloma 26 33 474 481 I-cancer
( 34 35 482 483 O
serum 35 40 483 488 B-clinical_variable
M 41 42 489 490 I-clinical_variable
- 42 43 490 491 I-clinical_variable
protein 43 50 491 498 I-clinical_variable
level 51 56 499 504 I-clinical_variable
> 57 58 505 506 O
= 58 59 506 507 O
0.5 60 63 508 511 B-lower_bound
g 64 65 512 513 I-lower_bound
/ 65 66 513 514 I-lower_bound
dL 66 68 514 516 I-lower_bound
or 69 71 517 519 O
urine 72 77 520 525 B-clinical_variable
M 78 79 526 527 I-clinical_variable
- 79 80 527 528 I-clinical_variable
protein 80 87 528 535 I-clinical_variable
level 88 93 536 541 I-clinical_variable
> 94 95 542 543 O
= 95 96 543 544 O
200 97 100 545 548 B-lower_bound
mg/24 101 106 549 554 I-lower_bound
hrs 107 110 555 558 I-lower_bound
) 110 111 558 559 O

Man 0 3 560 563 B-gender
, 3 4 563 564 O
who 5 8 565 568 O
is 9 11 569 571 O
sexually 12 20 572 580 O
active 21 27 581 587 O
with 28 32 588 592 O
a 33 34 593 594 O
woman 35 40 595 600 B-gender
of 41 43 601 603 O
child 44 49 604 609 O
- 49 50 609 610 O
bearing 50 57 610 617 O
potential 58 67 618 627 O
and 68 71 628 631 O
has 72 75 632 635 O
not 76 79 636 639 O
had 80 83 640 643 O
a 84 85 644 645 O
vasectomy 86 95 646 655 O
, 95 96 655 656 O
must 97 101 657 661 O
agree 102 107 662 667 B-contraception_consent
to 108 110 668 670 I-contraception_consent
use 111 114 671 674 I-contraception_consent
a 115 116 675 676 I-contraception_consent
barrier 117 124 677 684 I-contraception_consent
method 125 131 685 691 I-contraception_consent
of 132 134 692 694 I-contraception_consent
birth 135 140 695 700 I-contraception_consent
control 141 148 701 708 I-contraception_consent
example 149 156 709 716 O
( 157 158 717 718 O
eg 158 160 718 720 O
) 160 161 720 721 O
, 161 162 721 722 O
either 163 169 723 729 O
condom 170 176 730 736 B-contraception_consent
with 177 181 737 741 I-contraception_consent
spermicidal 182 193 742 753 I-contraception_consent
foam 194 198 754 758 I-contraception_consent
/ 198 199 758 759 I-contraception_consent
gel 199 202 759 762 I-contraception_consent
/ 202 203 762 763 I-contraception_consent
film 203 207 763 767 I-contraception_consent
/ 207 208 767 768 I-contraception_consent
cream 208 213 768 773 I-contraception_consent
/ 213 214 773 774 I-contraception_consent
suppository 214 225 774 785 I-contraception_consent

Participant 0 11 786 797 O
has 12 15 798 801 O
a 16 17 802 803 O
history 18 25 804 811 O
of 26 28 812 814 O
malignancy 29 39 815 825 B-cancer
( 40 41 826 827 O
other 41 46 827 832 O
than 47 51 833 837 O
multiple 52 60 838 846 B-cancer
myeloma 61 68 847 854 I-cancer
) 68 69 854 855 O
within 70 76 856 862 O
5 77 78 863 864 B-upper_bound
years 79 84 865 870 I-upper_bound
before 85 91 871 877 O
Cycle 92 97 878 883 O
1 98 99 884 885 O
Day 100 103 886 889 O
1 104 105 890 891 O

Participant 0 11 892 903 O
has 12 15 904 907 O
previously 16 26 908 918 O
received 27 35 919 927 O
an 36 38 928 930 O
allogenic 39 48 931 940 B-treatment
stem 49 53 941 945 I-treatment
cell 54 58 946 950 I-treatment
transplant 59 69 951 961 I-treatment

Participant 0 11 962 973 O
has 12 15 974 977 O
received 16 24 978 986 O
anti 25 29 987 991 B-treatment
- 29 30 991 992 I-treatment
myeloma 30 37 992 999 I-treatment
treatment 38 47 1000 1009 I-treatment
within 48 54 1010 1016 O
2 55 56 1017 1018 B-upper_bound
weeks 57 62 1019 1024 I-upper_bound
before 63 69 1025 1031 O
Cycle 70 75 1032 1037 O
1 76 77 1038 1039 O
Day 78 81 1040 1043 O
1 82 83 1044 1045 O

Participant 0 11 1046 1057 O
has 12 15 1058 1061 O
received 16 24 1062 1070 O
daratumumab 25 36 1071 1082 B-treatment
or 37 39 1083 1085 O
other 40 45 1086 1091 O
anti 46 50 1092 1096 B-treatment
- 50 51 1096 1097 I-treatment
cluster 51 58 1097 1104 I-treatment
of 59 61 1105 1107 I-treatment
differentiation 62 77 1108 1123 I-treatment
38 78 80 1124 1126 I-treatment
( 81 82 1127 1128 I-treatment
anti 82 86 1128 1132 I-treatment
- 86 87 1132 1133 I-treatment
CD38 87 91 1133 1137 I-treatment
) 91 92 1137 1138 I-treatment
therapies 93 102 1139 1148 I-treatment
previously 103 113 1149 1159 O

Participant 0 11 1160 1171 O
is 12 14 1172 1174 O
exhibiting 15 25 1175 1185 O
clinical 26 34 1186 1194 O
signs 35 40 1195 1200 O
of 41 43 1201 1203 O
meningeal 44 53 1204 1213 O
involvement 54 65 1214 1225 O
of 66 68 1226 1228 O
multiple 69 77 1229 1237 B-cancer
myeloma 78 85 1238 1245 I-cancer

Participant 0 11 1246 1257 O
must 12 16 1258 1262 O
have 17 21 1263 1267 O
an 22 24 1268 1270 O
Eastern 25 32 1271 1278 B-clinical_variable
Cooperative 33 44 1279 1290 I-clinical_variable
Oncology 45 53 1291 1299 I-clinical_variable
Group 54 59 1300 1305 I-clinical_variable
( 60 61 1306 1307 I-clinical_variable
ECOG 61 65 1307 1311 I-clinical_variable
) 65 66 1311 1312 I-clinical_variable
performance 67 78 1313 1324 I-clinical_variable
status 79 85 1325 1331 I-clinical_variable
score 86 91 1332 1337 O
of 92 94 1338 1340 O
0 95 96 1341 1342 B-lower_bound
, 96 97 1342 1343 O
1 98 99 1344 1345 O
, 99 100 1345 1346 O
or 101 103 1347 1349 O
2 104 105 1350 1351 B-upper_bound

Participants 0 12 1352 1364 O
proven 13 19 1365 1371 O
to 20 22 1372 1374 O
have 23 27 1375 1379 O
multiple 28 36 1380 1388 B-cancer
myeloma 37 44 1389 1396 I-cancer
( 45 46 1397 1398 I-cancer
MM 46 48 1398 1400 I-cancer
) 48 49 1400 1401 I-cancer
diagnosis 50 59 1402 1411 O
according 60 69 1412 1421 O
to 70 72 1422 1424 O
the 73 76 1425 1428 O
International 77 90 1429 1442 O
Myeloma 91 98 1443 1450 O
Working 99 106 1451 1458 O
Group 107 112 1459 1464 O
( 113 114 1465 1466 O
IMWG 114 118 1466 1470 O
) 118 119 1470 1471 O
diagnostic 120 130 1472 1482 O
criteria 131 139 1483 1491 O

Prior 0 5 1492 1497 B-treatment
lines 6 11 1498 1503 I-treatment
of 12 14 1504 1506 I-treatment
therapy 15 22 1507 1514 I-treatment
must 23 27 1515 1519 O
include 28 35 1520 1527 O
a 36 37 1528 1529 O
proteasome 38 48 1530 1540 B-treatment
inhibitor 49 58 1541 1550 I-treatment
( 59 60 1551 1552 I-treatment
PI 60 62 1552 1554 I-treatment
) 62 63 1554 1555 I-treatment
( 64 65 1556 1557 O
eg 65 67 1557 1559 O
, 67 68 1559 1560 O
bortezomib 69 79 1561 1571 B-treatment
, 79 80 1571 1572 O
carfilzomib 81 92 1573 1584 B-treatment
) 92 93 1584 1585 O

Prior 0 5 1586 1591 O
treatment 6 15 1592 1601 O
with 16 20 1602 1606 O
less 21 25 1607 1611 O
than 26 30 1612 1616 O
or 31 33 1617 1619 O
equal 34 39 1620 1625 O
to 40 42 1626 1628 O
( 43 44 1629 1630 O
> 44 45 1630 1631 O
=) 45 47 1631 1633 O
2 48 49 1634 1635 B-lower_bound
treatment 50 59 1636 1645 O
lines 60 65 1646 1651 O
of 66 68 1652 1654 O
anti 69 73 1655 1659 B-treatment
- 73 74 1659 1660 I-treatment
myeloma 74 81 1660 1667 I-treatment
therapy 82 89 1668 1675 I-treatment

Refractory 0 10 1676 1686 B-chronic_disease
disease 11 18 1687 1694 I-chronic_disease
is 19 21 1695 1697 O
defined 22 29 1698 1705 O
as 30 32 1706 1708 O
less 33 37 1709 1713 O
than 38 42 1714 1718 O
( 43 44 1719 1720 O
< 44 45 1720 1721 O
) 45 46 1721 1722 O
25 47 49 1723 1725 B-upper_bound
percent 50 57 1726 1733 I-upper_bound
( 58 59 1734 1735 I-upper_bound
% 59 60 1735 1736 I-upper_bound
) 60 61 1736 1737 I-upper_bound
reduction 62 71 1738 1747 O
in 72 74 1748 1750 O
M 75 76 1751 1752 O
- 76 77 1752 1753 O
protein 77 84 1753 1760 O
or 85 87 1761 1763 O
progression 88 99 1764 1775 O
of 100 102 1776 1778 O
disease 103 110 1779 1786 O
during 111 117 1787 1793 O
treatment 118 127 1794 1803 O

Relapsed 0 8 1804 1812 O
or 9 11 1813 1815 O
refractory 12 22 1816 1826 B-cancer
disease 23 30 1827 1834 I-cancer

all 0 3 1835 1838 O
men 4 7 1839 1842 B-gender
must 8 12 1843 1847 O
also 13 17 1848 1852 O
not 18 21 1853 1856 O
donate 22 28 1857 1863 O
sperm 29 34 1864 1869 O
during 35 41 1870 1876 O
the 42 45 1877 1880 O
study 46 51 1881 1886 O

an 0 2 1887 1889 O
immunomodulatory 3 19 1890 1906 B-treatment
drug 20 24 1907 1911 I-treatment
( 25 26 1912 1913 I-treatment
IMiD 26 30 1913 1917 I-treatment
) 30 31 1917 1918 I-treatment
( 32 33 1919 1920 O
example 33 40 1920 1927 O
, 40 41 1927 1928 O
thalidomide 42 53 1929 1940 B-treatment
, 53 54 1940 1941 O
lenalidomide 55 67 1942 1954 B-treatment
, 67 68 1954 1955 O
pomalidomide 69 81 1956 1968 B-treatment
) 81 82 1968 1969 O
in 83 85 1970 1972 O
any 86 89 1973 1976 O
order 90 95 1977 1982 O
during 96 102 1983 1989 O
the 103 106 1990 1993 O
course 107 113 1994 2000 O
of 114 116 2001 2003 O
treatment 117 126 2004 2013 B-treatment

immunoglobulin 0 14 2014 2028 B-cancer
( 15 16 2029 2030 I-cancer
Ig 16 18 2030 2032 I-cancer
) 18 19 2032 2033 I-cancer
G 20 21 2034 2035 I-cancer
myeloma 22 29 2036 2043 I-cancer
( 30 31 2044 2045 O
serum 31 36 2045 2050 B-clinical_variable
monoclonal 37 47 2051 2061 I-clinical_variable
paraprotein 48 59 2062 2073 I-clinical_variable
[ 60 61 2074 2075 I-clinical_variable
M 61 62 2075 2076 I-clinical_variable
- 62 63 2076 2077 I-clinical_variable
protein 63 70 2077 2084 I-clinical_variable
] 70 71 2084 2085 I-clinical_variable
level 72 77 2086 2091 I-clinical_variable
> 78 79 2092 2093 O
= 79 80 2093 2094 O
1.0 80 83 2094 2097 B-lower_bound
gram 84 88 2098 2102 I-lower_bound
/ 88 89 2102 2103 I-lower_bound
deciliter 89 98 2103 2112 I-lower_bound
[ 99 100 2113 2114 I-lower_bound
g 100 101 2114 2115 I-lower_bound
/ 101 102 2115 2116 I-lower_bound
dL 102 104 2116 2118 I-lower_bound
] 104 105 2118 2119 I-lower_bound
or 106 108 2120 2122 O
urine 109 114 2123 2128 B-clinical_variable
M 115 116 2129 2130 I-clinical_variable
- 116 117 2130 2131 I-clinical_variable
protein 117 124 2131 2138 I-clinical_variable
level 125 130 2139 2144 I-clinical_variable
greater 131 138 2145 2152 O
than 139 143 2153 2157 O
or 144 146 2158 2160 O
equal 147 152 2161 2166 O
to 153 155 2167 2169 O
( 156 157 2170 2171 O
> 157 158 2171 2172 O
=) 158 160 2172 2174 O
200 161 164 2175 2178 B-lower_bound
milligram[mg]/24 165 181 2179 2195 I-lower_bound
hours[hrs 182 191 2196 2205 I-lower_bound
] 191 192 2205 2206 I-lower_bound

light 0 5 2207 2212 B-cancer
chain 6 11 2213 2218 I-cancer
multiple 12 20 2219 2227 I-cancer
myeloma 21 28 2228 2235 I-cancer
( 29 30 2236 2237 O
serum 30 35 2237 2242 B-clinical_variable
immunoglobulin 36 50 2243 2257 I-clinical_variable
free 51 55 2258 2262 I-clinical_variable
light 56 61 2263 2268 I-clinical_variable
chain 62 67 2269 2274 I-clinical_variable
> 68 69 2275 2276 O
= 69 70 2276 2277 O
10 70 72 2277 2279 B-lower_bound
mg 73 75 2280 2282 I-lower_bound
/ 75 76 2282 2283 I-lower_bound
dL 76 78 2283 2285 I-lower_bound
and 79 82 2286 2289 O
abnormal 83 91 2290 2298 O
serum 92 97 2299 2304 O
immunoglobulin 98 112 2305 2319 O
kappa 113 118 2320 2325 O
lambda 119 125 2326 2332 O
free 126 130 2333 2337 O
light 131 136 2338 2343 O
chain 137 142 2344 2349 O
ratio 143 148 2350 2355 O
) 148 149 2355 2356 O

more 0 4 2357 2361 O
than 5 9 2362 2366 O
60 10 12 2367 2369 B-lower_bound
days 13 17 2370 2374 I-lower_bound
after 18 23 2375 2380 O
cessation 24 33 2381 2390 O
of 34 36 2391 2393 O
treatment 37 46 2394 2403 O

participant 0 11 2404 2415 O
has 12 15 2416 2419 O
received 16 24 2420 2428 O
autologous 25 35 2429 2439 B-treatment
stem 36 40 2440 2444 I-treatment
cell 41 45 2445 2449 I-treatment
transplantation 46 61 2450 2465 I-treatment
( 62 63 2466 2467 I-treatment
ASCT 63 67 2467 2471 I-treatment
) 67 68 2471 2472 I-treatment
within 69 75 2473 2479 O
12 76 78 2480 2482 B-upper_bound
weeks 79 84 2483 2488 I-upper_bound
before 85 91 2489 2495 O
Cycle 92 97 2496 2501 O
1 98 99 2502 2503 O
Day 100 103 2504 2507 O
1 104 105 2508 2509 O

within 0 6 2510 2516 O
60 7 9 2517 2519 B-upper_bound
days 10 14 2520 2524 I-upper_bound
after 15 20 2525 2530 O
cessation 21 30 2531 2540 O
of 31 33 2541 2543 O
treatment 34 43 2544 2553 O

